dexrazoxane

Overview
Prescribing Info
Drug Label Annotations
Clinical Annotations
Variant Annotations
Literature
Pathways
Related To
Links
Navigate to...
Show section selector dropdown

Literature

The publications shown below are associated with this chemical in PharmGKB based on (1) literature annotations, (2) variant annotations, (3) VIP summaries, or (4) pathways.

    9 items
    Literature
    Prevention of cardiotoxicity among survivors of childhood cancer.
    British journal of clinical pharmacology. 2017. Hutchins Kelley K, Siddeek Hani, Franco Vivian I and Lipshultz Steven E.
    Literature
    Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.
    Pharmacogenomics. 2013. Jensen Brian C and McLeod Howard L.
    Literature
    New developments in anthracycline-induced cardiotoxicity.
    Current medicinal chemistry. 2009. Mordente A, Meucci E, Silvestrini A, Martorana G E and Giardina B.
    Literature
    Cardioprotective interventions for cancer patients receiving anthracyclines.
    The Cochrane database of systematic reviews. 2008. van Dalen E C, Caron H N, Dickinson H O and Kremer L C M.
    Literature
    Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.
    Methods in enzymology. 2004. Minotti Giorgio, Recalcati Stefania, Menna Pierantonio, Salvatorelli Emanuela, Corna Gianfranca and Cairo Gaetano.
    Literature
    Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Drugs. 1998. Wiseman L R and Spencer C M.
    Literature
    Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997. Swain S M, Whaley F S, Gerber M C, Weisberg S, York M, Spicer D, Jones S E, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer M S, Bianchine J R and Gams R A.
    Literature
    Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997. Swain S M, Whaley F S, Gerber M C, Ewer M S, Bianchine J R and Gams R A.
    Literature
    Phase I study of ICRF-187 using a daily for 3 days schedule.
    Cancer treatment reports. 1981. Von Hoff D D, Howser D, Lewis B J, Holcenberg J, Weiss R B and Young R C.
    Pediatric